Three health-related Massachusetts companies are expected to go public next week, according to a release from a company that manages IPO-focused exchanged traded funds.
Renaissance Capital, a company that manages IPO-focused exchange-traded funds, said that two Cambridge-based biotechnology companies — Seres Therapeutics and Catabasis Pharmaceuticals —that have filed for initial public offerings are expected to go public next week. Sere said it would sell 6.3 million shares for around $16 each, hoping to raise about $100 million. Catabasis hopes to sell 4.3 million shares for around $14 each, raising $60 million.
Seres develops ways to replace colon bacteria to treat infections, while Catabasis develops theories for the treatment of rare diseases.
North-Billerica-based Lantheus Holdings, a company that sells imaging systems for diagnosing cardiovascular diseases, also expects to go public next week, hoping to sell 7.9 million shares for roughly $10 each, raising $75 million.
Kathleen Smith of Renaissance said that while biotechnology companies don’t always have a sure bet in the market, the handful that do fare well, trade exceptionally well.
“The IPO market has been healthy not because the number of deals have been over the top, but because the returns have been good,” Smith said.
While this year is not as active as last year, this month is shaping up with be the most active June for IPOs since 2000.
Karishma Mehrotra can be reached at firstname.lastname@example.org. Follow her on Twitter @missmishma.